MedTrace Logo

Metabolic Actions of Omega-3 Fatty Acids

NCT01896414 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-01-14

No results posted yet for this study

Summary

The metabolic syndrome raises the risk of heart disease and is currently at epidemic proportions in the U.S. It consists of 3 of the following components: central obesity, high triglycerides, low HDL, abnormal blood pressure and impaired fasting glucose levels. Previous studies have suggested that omega-3 fish oil may influence some of these components but the mechanisms involved are not well understood. Therefore, this proposal will investigate how omega-3 fish oils affect inflammation, lipids and fat breakdown by comparing it to placebo. Favorable outcomes from this study could translate into a new approach to improve heart disease risk in men and women with the metabolic syndrome.

Conditions

  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

EPA (marine fatty acids)

Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.

DIETARY_SUPPLEMENT

Placebo

Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • US Department of Veterans Affairs

    collaborator FED

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Michael Miller, M.D. · University of Maryland, College Park

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-05-30
Completion
2016-05-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01896414 on ClinicalTrials.gov